scholarly journals Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ting Chen ◽  
Jiayi Song ◽  
Hongli Liu ◽  
Hongmei Zheng ◽  
Changzheng Chen
Keyword(s):  
Epstein Barr Virus ◽  
Virus Detection ◽  
Onset Time ◽  
Viral Capsid Antigen ◽  
C Reactive Protein ◽  
Barr Virus ◽  
Reactive Protein ◽  
Single Center Study ◽  
High Incidence ◽  
Epstein Barr

AbstractThe objective of this study was to detect the Epstein–Barr virus (EBV) coinfection in coronavirus disease 2019 (COVID-19). In this retrospective single-center study, we included 67 COVID-19 patients with onset time within 2 weeks in Renmin Hospital of Wuhan University from January 9 to February 29, 2020. Patients were divided into EBV/SARS-CoV-2 coinfection group and SARS-CoV-2 infection alone group according to the serological results of EBV, and the characteristics differences between the two groups were compared. The median age was 37 years, with 35 (52.2%) females. Among these COVID-19 patients, thirty-seven (55.2%) patients were seropositive for EBV viral capsid antigen (VCA) IgM antibody. EBV/SARS-CoV-2 coinfection patients had a 3.09-fold risk of having a fever symptom than SARS-CoV-2 infection alone patients (95% CI 1.11–8.56; P = 0.03). C-reactive protein (CRP) (P = 0.02) and the aspartate aminotransferase (AST) (P = 0.04) in EBV/SARS-CoV-2 coinfection patients were higher than that in SARS-CoV-2 infection alone patients. EBV/SARS-CoV-2 coinfection patients had a higher portion of corticosteroid use than the SARS-CoV-2 infection alone patients (P = 0.03). We find a high incidence of EBV coinfection in COVID-19 patients. EBV/SARS-CoV-2 coinfection was associated with fever and increased inflammation. EBV reactivation may associated with the severity of COVID-19.

scholarly journals Positive Epstein-Barr virus detection in corona virus disease 2019 (COVID-19) patients

2020 ◽  
Author(s):  
Ting Chen ◽  
Jiayi Song ◽  
Hongli Liu ◽  
Hongmei Zheng ◽  
Changzheng Chen
Keyword(s):  
Epstein Barr Virus ◽  
Virus Disease ◽  
Acute Infection ◽  
Virus Detection ◽  
C Reactive Protein ◽  
Barr Virus ◽  
Reactive Protein ◽  
Corona Virus ◽  
Single Center Study ◽  
Epstein Barr

Abstract Background Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of corona virus disease 2019 (COVID-19) in Wuhan, China. The Objective of this study was to detect the EBV coinfection in COVID-19.Methods In this retrospective single-center study, we included 67 patients with confirmed COVID-19 in Renmin Hospital of Wuhan University from January 9 to February 29, 2020. Patients were divided into EBV seropositive group and seronegative group according to the serological results of EBV, and the characteristics differences between the two groups were compared.Results 67 COVID-19 patients were included in our study. The median age was 37 years, with 35 (52.2%) females. Among these COVID-19 patients, 37 (55.2%) patients were seropositive for EBV viral capsid antigen (VCA) IgM antibody. EBV seropositive COVID-19 patients had a 3.09-fold risk of having a fever symptom than EBV seronegative (95%CI, 1.11-8.56; P=0.03). C-reactive protein (CRP) (P=0.02) and the aspartate aminotransferase (AST) (P=0.04) in EBV seropositive COVID-19 patients were higher than that in EBV seronegative patients. EB seropositive patients had a higher portion of corticosteroid use than the EB seronegative patients (P=0.03).Conclusions EBV acute infection was found in COVID-19 patients. EBV seropositivity was associated with fever and increased inflammation. EBV reactivation may affected the treatment of COVID-19.

Relationship between biological and self-reported measures of stress among informal caregivers of patients with prostate cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 18506-18506
Author(s):  
W. P. Witt ◽  
S. Pickard ◽  
T. Kuzel ◽  
T. McDade ◽  
S. Perry ◽  
...  
Keyword(s):  
Mental Health ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Epstein Barr Virus ◽  
Informal Caregivers ◽  
C Reactive Protein ◽  
Barr Virus ◽  
Reactive Protein ◽  
Biological Stress ◽  
Epstein Barr

18506 Background: Informal caregivers of prostate cancer patients often experience chronic psychological stress that may adversely impact their physical and mental health, and their ability to care for their families and the patient. This study aims to determine the association between perceived and biological stress among informal caregivers of prostate cancer patients. Methods: A total of 24 informal caregivers of prostate cancer patients were recruited from both the Jesse Brown VA Center (Lakeside and Westside, Chicago) and the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. Caregivers completed self-reported measures of stress, somatization, life events, burden, health status (SF-36) and mental health. Capillary blood spot samples from caregivers were used to examine two measures of biological stress, Epstein-Barr virus antibody titer and C-reactive protein. Results: Informal caregivers had a mean age of 63 years and were mostly female and spouses of patients with prostate cancer. Many had preexisting co-morbidities, including 45.8% with hypertension, 45.8% with arthritis, and 33.3% with diabetes. Nearly 30% had been hospitalized in the last 12 months. 33.3% of caregivers experienced at least one major life event in the last year and 62.5% had symptoms of somatization illness. Caregivers with symptoms of somatization illness had higher mean Epstein-Barr antibody titers as compared with those without symptoms (Mean EBV antibody titer: 198.3 versus 141.8, respectively (p < 0.05)). Caregiver-reported measures were not correlated with C-reactive protein levels. Caregivers with higher levels of strain perceived more stress in their lives (p < 0.05), but showed relatively high self-esteem (mean = 30.6, SD = 2.8, on a 7–35 scale). Conclusions: These preliminary findings suggest that informal caregivers who report symptoms of somatization illness exhibit signs of relative suppression of the cell-mediated immune processes as a result of the reactivation of the Epstein-Barr virus. Final analyses will be conducted that control for potential confounders and will further elucidate if caregiver stress is associated with suppression of the immune system. No significant financial relationships to disclose.

scholarly journals The role of C-reactive protein, neopterin and melatonin in the diagnosis of Epstein-Barr virus infection

Immunologiya ◽  
2021 ◽  
Vol 42 (5) ◽  
pp. 502-510
Author(s):  
T.V. Solomay ◽  
◽  
T.A. Semenenko ◽  
T.P. Gotvyanskaya ◽  
M.V. Konopleva ◽  
...  
Keyword(s):  
Virus Infection ◽  
Epstein Barr Virus ◽  
Epstein Barr Virus Infection ◽  
C Reactive Protein ◽  
Barr Virus ◽  
Reactive Protein ◽  
Epstein Barr ◽  
Barr Virus Infection

Cost-Effectiveness of Nasopharyngeal Carcinoma Screening with Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations Worldwide

2020 ◽  
Author(s):  
Jacob A Miller ◽  
Quynh-Thu Le ◽  
Benjamin A Pinsky ◽  
Hannah Wang
Keyword(s):  
Cost Effectiveness ◽  
Epstein Barr Virus ◽  
Cost Effective ◽  
Chain Reaction ◽  
Men And Women ◽  
Barr Virus ◽  
Screening Strategies ◽  
High Incidence ◽  
Polymerase Chain ◽  
Epstein Barr

Abstract Background The incidence of endemic Epstein-Barr Virus (EBV)-associated nasopharyngeal carcinoma (NPC) varies considerably worldwide. In high-incidence regions, screening trials have been conducted. We estimated the mortality reduction and cost-effectiveness of EBV-based NPC screening in populations worldwide. Methods We identified 380 populations in 132 countries with incident NPC and developed a decision-analytic model to compare ten unique onetime screening strategies to no screening for men and women at age 50 years. Screening performance and the stage distribution of undiagnosed NPC were derived from a systematic review of prospective screening trials. Results Screening was cost-effective in up to 14.5% of populations, depending on the screening strategy. These populations were limited to East Asia, Southeast Asia, North Africa, or were Asian, Pacific Islander, or Inuit populations in North America. A combination of serology and nasopharyngeal polymerase chain reaction (PCR) was most cost-effective, but other combinations of serologic and/or plasma PCR screening were also cost-effective. The estimated reduction in NPC mortality was similar across screening strategies. For a hypothetical cohort of patients in China, 10-year survival improved from 71.0% (95%CI = 68.8%–73.0%) without screening to a median of 86.3% (range = 83.5%–88.2%) with screening. This corresponded to a median 10-year reduction in NPC mortality of 52.9% (range= 43.1%–59.3%). Screening interval impacted absolute mortality reduction and cost-effectiveness. Conclusions We observed decreased NPC mortality with EBV-based screening. Screening was cost-effective in many high-incidence populations and could be extended to men and women as early as age 40 years in select regions. These findings may be useful when choosing among local public health initiatives.

Sign in / Sign up

Export Citation Format

Share Document